EFPIA - NEWSLETTER

EFPIA Newsletter 09 July 2026

The Biotech Act can help Europe compete again in life sciences but on its own cannot deliver the change that Europe urgently requires

By Nathalie Moll, Director General, EFPIA

Europe has enormous strengths in science, manufacturing and its industrial base, but struggles to translate this into investment, clinical trials and new medicines. Faced with rising global competition, a more ambitious approach is needed.

The rationale for strengthening Europe’s position in the global life sciences ecosystem is clear. If Europe can match or exceed the pace and scale of other regions, it will mean stronger growth, more high-value jobs, and better health for our populations.

How a European cardiovascular strategy could reshape prevention across Member States

With cardiovascular disease still causing millions of deaths across Europe, attention is turning to how prevention, screening and integrated primary care can become more accessible and standardised across Member States.

At an event held by EFPIA and the European Alliance for Cardiovascular Health (EACH) at the European Parliament, policymakers, patient advocates and healthcare stakeholders gathered to discuss how Europe can strengthen cardiovascular prevention through earlier detection and structured health checks, as the European Union prepares its upcoming Council Recommendation under the Safe Hearts Plan.

Read more here.

What does life sciences competitiveness look like around the world?

EFPIA's latest analysis, now expanded to include Japan, shows that the EU and Japan are at a similar crossroads. Both have strong scientific foundations and globally recognised pharmaceutical industries, yet face increasing competition from countries that are making life sciences innovation a strategic economic and industrial priority.

Find out more here about strengths and weaknesses of each region and what it will take to remain globally competitive.

Events

14 OCT 2026

Momentum 2026 – Accelerating Europe’s action on cancer Artipelag, Stockholm

Europe produces world-class cancer research, yet too often patients wait too long to benefit from scientific progress....

Learn more →

17 NOV 2026

20th Global Forum for Qualified Persons for Pharmacovigilance (QPPV) Amsterdam, The Netherlands

20 years of QPPVs talking to QPPVs. The DIA Global QPPV Forum — a trusted space for QPPVs, NCPs and PV professionals...

Learn more →

Europe must act to restore biotech competitiveness, industry warns

In this interview, Olaf Weppner, Vice President for Europe Region North at AbbVie, discusses the challenges shaping the region’s biotech sector. He highlights Europe’s strong scientific base, skilled workforce, and research infrastructure, while pointing to a decline in global competitiveness, including reduced clinical trial activity and increasing competition from other regions.

Watch the full interview here.

What are we reading

Building the future of health in Europe 07 July 2026 (The European Files)

Health is the most important contributor to well-being, cited by 51% of respondents 03 July 2026 (EU Barometer)

The need for European countries to complement EU-level pull incentives with national provisions... 29 June 2026 (CRA)

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
Communications@efpia.eu

▶